Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE1 trial investigates HIV and is currently actively recruiting participants. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
4 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE1
-
Jul 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — Jul 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .